Oppenheimer Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-10,476
| Closed | -$650K | – | 1191 |
|
|
2020
Q4 | $650K | Buy |
10,476
+154
| +1% | +$9.56K | 0.01% | 812 |
|
|
2020
Q3 | $614K | Buy |
10,322
+1,808
| +21% | +$108K | 0.01% | 762 |
|
|
2020
Q2 | $594K | Buy |
8,514
+2,054
| +32% | +$143K | 0.01% | 747 |
|
|
2020
Q1 | $293K | Buy |
+6,460
| New | +$293K | 0.01% | 872 |
|
|
2019
Q3 | – | Sell |
-1,297
| Closed | -$93K | – | 1621 |
|
|
2019
Q2 | $93K | Sell |
1,297
-118
| -8% | -$8.46K | ﹤0.01% | 1242 |
|
|
2019
Q1 | $111K | Sell |
1,415
-360
| -20% | -$28.2K | ﹤0.01% | 1179 |
|
|
2018
Q4 | $150K | Buy |
+1,775
| New | +$150K | ﹤0.01% | 1086 |
|
|
2017
Q4 | – | Sell |
-478
| Closed | -$41K | – | 1296 |
|
|
2017
Q3 | $41K | Buy |
+478
| New | +$41K | ﹤0.01% | 1410 |
|